Transient Elastography (TE) is a Useful Tool for Assessing the Response of Liver Iron Chelation in Sickle Cell Disease Patients

Sophia Delicou¹, Konstantinos Maragkos¹, Maria Tambaki², Dimitrios Kountouras² and John Koskinas².

¹ Thalassemia and Sickle Cell Disease Department, Hippocratio General Hospital Athens.
² Second Academic Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital Athens.

Competing interests: The authors have declared that no competing interests exist.

Abstract. Sickle cell disease patients often need regular blood transfusions to improve both the quality of life and survival from the veno-occlusive complications of the disease. Deferasirox, a convenient long acting oral agent, has recently been introduced in clinical practice with promising efficacy. This study aims to evaluate the association of liver stiffness and possible fibrosis with iron deposition and confirm the use of elastography as a validated test of responding to chelation with low cost and easy access. 15 patients with sickle cell disease and systemic or occasional transfusions were evaluated with MRI, transient elastography and biochemistry, for liver iron (LIC) and liver stiffness (LSM) before onset and one year after taking Deferasirox. All patients completed the study. Our results showed improvement in hepatic iron and hepatic stiffness after chelation therapy; Furthermore ALT, AST, LDH and ferritin levels have improved after 12 months of therapy with deferasirox. During the study no serious adverse events were encountered indicating the safety of the drug. Transient liver elastography findings correlate with serum ferritin and LIC in patients with sickle cell disease and it is a useful tool for assessing the response of liver iron chelation therapy.

Keywords: Sickle cell disease, Iron chelation, Transient elastography, Transfusion, Iron overload.

Citation: Delicou S., Maragkos K., Tambaki M., Kountouras D., Koskinas J. Transient elastography (TE) is a useful tool for assessing the response of liver iron chelation in sickle cell disease patients. Mediterr J Hematol Infect Dis 2018, 10(1): e2018049, DOI: http://dx.doi.org/10.4084/MJHID.2018.049

Published: September 1, 2018 Received: April 24, 2018 Accepted: August 6, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Sophia Delicou – MD, Hematologist, Thalassemia and Sickle Cell Department, Hippocratio General Hospital Athens. Address:114 Leof. Vasilissis Sofias, Athens 115 27. E-mail: sophiadelicou@hippocratio.gr

Introduction. Chronic transfusion therapy is being used more frequently to prevent and treat the complications of sickle cell disease. Previous studies have shown that the iron overload that results from such therapy in other patient populations is associated with significant morbidity and mortality.¹ Deferoxamine has been the standard drug for iron chelation therapy over the past four decades. However, its major disadvantage is non-compliance of patients, because it needs an 8- to 12-hr parenteral administration since it has a short half-life and a very poor oral bioavailability. Deferiprone was the first extensively studied oral chelating agent in the early 2000s for patients who were unable to use deferoxamine effectively or safely. Although deferiprone-treated patients had good compliance in thalassemic patients, some serious side effects
such as neutropenia and agranulocytosis were reported that limited its use in sickle cell disease patients especially in combination with hydroxyurea.\textsuperscript{13}

A more convenient oral iron chelator, deferasirox, has recently become available showing promising efficacy. Many studies have shown that deferasirox has an acceptable profile of safety and tolerability in thalassemic patients.\textsuperscript{2,4,5}

Liver iron concentration has been regarded as the reference standard for estimating body iron load in thalassemic patients and has been shown to predict total body iron stores accurately. In sickle cell anemia, the liver is one of the target organs of the disease itself, except the transfusional iron overload. The term "sickle cell hepatopathy" has sometimes been used to reflect the overlapping acute and chronic causes of liver dysfunction in these patients. Studies in patients that have been hospitalized due to an acute vasoocclusive crisis have estimated the frequency of liver involvement ranging from 10% to 39% and an autopsy study of sickle cell patients has revealed the presence of hepatic infarction in 34% of patients.\textsuperscript{6,7}

Prior studies have based on data from hereditary hemochromatosis and thalassemia major showing that elevated hepatic iron content determined by liver biopsy and imaging techniques over 7 mg/g liver dry weight is a risk factor for hepatic fibrosis. Therefore this value has been used as a guide to start chelation therapy.\textsuperscript{4,5,7,8}

Transient elastography and has been extensively validated in chronic liver diseases and is currently used for detection and staging of liver fibrosis.

In the last few years, liver stiffness measurement (LSM) by transient elastography (TE) has been shown to be closely related to the degree of hepatic fibrosis assessed by biopsy in thalassemic patients.\textsuperscript{9,10}

However, hepatic involvement has been shown to affect liver stiffness in patients with sickle cell disease during acute vaso-occlusive crisis measured with transient elastography.\textsuperscript{11}

The study aimed to evaluate the role of elastography (Liver Stiffness Measurement, LSM, kPascals, FibroScan, Echosens, Paris, France) in patients with SCD and explore possible correlations with clinical and laboratory characteristics, mainly those associated with iron overload.

Materials and Methods.

Study Design and Patient Population. Patients maintained on transfusion therapy either currently, or previously, were screened for eligibility between April 2014 and April 2015.

Fifteen patients with SCD who are followed-up in the Thalassemia and Sickle Cell Unit of Hippokratieon General Hospital in Athens, Greece were enrolled in the study. All patients completed the study.

Five patients had HbS/HbS, and thirteen had HbS/beta-thal; their median age was 45.8 years (range: 19–75 years). Seven patients were males and eight females.

Patients received regular blood transfusions or had sporadically transfused with at least 20 units of packed red blood cells during the last five years. Exchange or simple transfusions were allowed. Transfused red cells were negative for hemoglobin S, phenotypically matched and depleted of leukocytes and were delivered in a volume of approximately 10 to 15 ml per kilogram of packed cells per transfusion. The goal of the transfusion protocol for all patients was to maintain their hemoglobin S (HbS) percentage at or below 50% and the pre-hemoglobin and post-hemoglobin greater than 9 g/dL and less than 12 g/dL, respectively.

The initial dose of DFX was calculated based on the patient's body weight (10-40 mg/kg/day). The 20-mg/kg dose was considered appropriate for patients requiring reduction of a moderate iron burden, and a higher dose of 30-40 mg/kg was felt to be appropriate for patients with high iron burdens requiring major reduction of excess iron. Lower doses of 10-mg/kg were selected for maintenance use in patients with lower LIC values. DFX was taken daily every morning 30 minutes before breakfast, dispersed in a glass of water. Prior chelation therapy was permitted but was not mandatory. The serum ferritin level for entry into the study was ≥500 μg/l.

Patients eligible for entry into the study had performed MRI using a multi-gradient recalled echo (MGRE) sequence which allowed the determination of liver T2*, a relaxation time constant sensitive to the presence of liver iron, inversely proportional to liver LIC (Liver Iron Concentration).

They also had performed Liver stiffness measurement (LSM) using transient elastography (Fibroscan). A pulse-echo ultrasound acquisition is
used to follow the propagation of the shear wave and to measure its velocity, which is directly related to tissue stiffness and the severity of liver fibrosis.

The patients were evaluated at the enrollment and at the end of the study. Laboratory assessments were performed at least monthly and included complete blood counts with differential counts; Alanine Transaminase [ALT], Aspartate Transaminase [AST] Lactate Dehydrogenase [LDH] and ferritin. The concentrations of high sensitive C-reactive protein were also evaluated.

Urinary testing performed on random collections included determination of creatinine, total protein, and albumin. Physical examinations, electrocardiograms (ECGs), audiometry and ophthalmological tests were performed at baseline. The study duration was 52 weeks (12 months).

Patients were excluded if they had a serum creatinine above the upper limit of normal if they had significant proteinuria or if they had active or chronic hepatitis B or C. Other exclusion criteria were second and third atrioventricular block, QT interval prolongation, or therapy with digoxin or similar medications. Treatment with angiotensin converting enzyme inhibitors was permitted. Patients with chelation therapy, a significant improvement in LIC from 2373.33 to 1532 ng/ml range: 210-6300, p=0.002 (Figure A2).

The above findings were followed by an improvement in liver stiffness from 9.7 kPa to 6.7 kPa range: 5.1-10.1, p=0.001 (Figure A3). A significant improvement in AST, ALT, and LDH at 52 weeks was also noted. There was no significant difference in hs-CRP and serum creatinine from baseline to end of the study.

A significant correlation (r1: pre-treatment, r2: after treatment) between ferritin levels and LIC (r1=0.862 and r2=0.9298) and between ferritin and LSM (r1=0.6905 r2=0.7936) was found respectively. Furthermore, the correlation between LIC and LSM was statistically significant at baseline (r1=0.6344) and at the end of the study (r2=0.6075). No correlations were found between the other parameters (Table 2).

**Results.** The study completed 15 patients. Summary of the parameters and evaluated values at baseline and at the end of the study are given in **Table 1**.

After 12 months (52 weeks) of deferasirox therapy, a significant improvement in LIC from 7.86 to 5.62 mg range:3.1-20.1 mg Fe/g dry weight p=0.043 was found (Figure A1), followed by significant improvement of serum ferritin mean from 2373.33 to 1532 ng/ml range: 210-6300, p=0.002 (Figure A2).

**Statistical analysis.** Data are reported as mean ± SD. Comparisons among groups were made using one-way analysis of variation (ANOVA) analyses, where P < 0.05 was considered statistically significant.

**Table 1.** Summary of the parameters and evaluated values at baseline and at the end of the study.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline n=15</th>
<th>Range</th>
<th>End of study n=15</th>
<th>Range</th>
<th>P ≤0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibroscan (kPa)</td>
<td>9.7</td>
<td>5.6-14.2 (±2.56)</td>
<td>6.9</td>
<td>5.1- 10.1 (±1.78)</td>
<td>0.001</td>
</tr>
<tr>
<td>LIC mg Fe/g dw</td>
<td>7.86</td>
<td>4.1- 29.8 (±1.7)</td>
<td>5.62</td>
<td>3.1-20.1 (±1.13)</td>
<td>0.043</td>
</tr>
<tr>
<td>Ferritin ng/ml</td>
<td>2373.33</td>
<td>510-7890 (±536.1)</td>
<td>1532</td>
<td>210-6300 (±416.6)</td>
<td>0.002</td>
</tr>
<tr>
<td>CRP mg/l</td>
<td>2.7</td>
<td>2.2- 3.2 (±0.24)</td>
<td>2.5</td>
<td>2.0-3.03 (±0.24)</td>
<td>0.25</td>
</tr>
<tr>
<td>AST IU/L</td>
<td>64.5</td>
<td>55.9-73.1 (±4.0)</td>
<td>45</td>
<td>39-51.5 (±2.9)</td>
<td>0.002</td>
</tr>
<tr>
<td>ALT IU/L</td>
<td>48</td>
<td>45-110 (±5.8)</td>
<td>34.8</td>
<td>32.6-70 (±2.6)</td>
<td>0.010</td>
</tr>
<tr>
<td>LDH IU/L</td>
<td>416</td>
<td>210-710 (±43.9)</td>
<td>240</td>
<td>140-310 (±54.3)</td>
<td>0.0010</td>
</tr>
<tr>
<td>Creatinine mg/dl</td>
<td>0.8</td>
<td>0.6-1.5 (±0.02)</td>
<td>0.9</td>
<td>0.7-1.5 (±0.2)</td>
<td>0.094</td>
</tr>
</tbody>
</table>
Figure A1. Comparison of LIC in patients with Sickle Cell Disease who had received chelation therapy for 12 months revealed significant improvement (lic1: pre-treatment, lic2: end of study).

Figure A2. Comparison of ferritin in patients with Sickle Cell Disease who had received chelation therapy for 12 months revealed significant improvement (ferritin1: pre-treatment, ferritin2: end of the study).

Figure A3. Comparison of LSM in patients with Sickle Cell Disease who had received chelation therapy for 12 months revealed significant improvement (f1: pre-treatment, f2: end of the study).

Table 2. Correlations between all parameters.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>P&lt;0.05</th>
<th></th>
<th>End of study</th>
<th>P&lt;0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferritin/LIC</td>
<td>R₁=0.862</td>
<td>&lt; 0.00001</td>
<td></td>
<td>R₂=0.9298</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>LIC/LSM</td>
<td>R₁=0.6905</td>
<td>0.0044</td>
<td></td>
<td>R₂=0.7936</td>
<td>0.0004</td>
</tr>
<tr>
<td>LIC/LSM</td>
<td>R₁=0.6344</td>
<td>0.0111</td>
<td></td>
<td>R₂=0.6075</td>
<td>0.0163</td>
</tr>
<tr>
<td>AST/ferritin</td>
<td>R₁=0.3642</td>
<td>0.1820</td>
<td></td>
<td>R₂=0.3995</td>
<td>0.1401</td>
</tr>
<tr>
<td>ALT/ferritin</td>
<td>R₁=0.5050</td>
<td>0.0549</td>
<td></td>
<td>R₂=0.4872</td>
<td>0.0655</td>
</tr>
<tr>
<td>AST/LSM</td>
<td>R₁=0.5393</td>
<td>0.080</td>
<td></td>
<td>R₂=0.4451</td>
<td>0.0964</td>
</tr>
<tr>
<td>AST/LIC</td>
<td>R₁=0.1089</td>
<td>0.6994</td>
<td></td>
<td>R₂=0.273</td>
<td>0.3246</td>
</tr>
<tr>
<td>ALT/LSM</td>
<td>R₁=0.4622</td>
<td>0.0828</td>
<td></td>
<td>R₂=0.4409</td>
<td>0.1000</td>
</tr>
<tr>
<td>ALT/LIC</td>
<td>R₁=0.3184</td>
<td>0.2475</td>
<td></td>
<td>R₂=0.3742</td>
<td>0.1694</td>
</tr>
<tr>
<td>LDH/LSM</td>
<td>R₁=0.2376</td>
<td>0.3938</td>
<td></td>
<td>R₂=0.2304</td>
<td>0.4087</td>
</tr>
<tr>
<td>LDH/LIC</td>
<td>R₁=0.035</td>
<td>0.9009</td>
<td></td>
<td>R₂=-0.013</td>
<td>0.9607</td>
</tr>
<tr>
<td>Ferritin/CRP</td>
<td>R₁=-0.1223</td>
<td>0.6642</td>
<td></td>
<td>R₂=-0.01139</td>
<td>0.9679</td>
</tr>
</tbody>
</table>

Safety and tolerability. During the study 39 Adverse Events were reported. The most common AEs reported were abdominal pain 41% (7/39), diarrhea 38.5% (15/39), nausea 10.3% (4/39), and nasopharyngitis 7.7% (3/39). Nausea and abdominal pain were reported on the same day in those patients. Sickle cell painful crisis 2.6% (1/39) was managed at home. No serious AEs were experienced during the study.

Serum creatinine levels were mostly stable during the study. Calculated creatinine clearance with Cockcroft and Gault formula remained stable during deferasirox treatment. Eight patients who received concomitant hydroxycarbamide during
the study remained relatively stable in the liver and renal function.

Discussion. Transfusion therapy is a key intervention in decreasing morbidity and mortality in patients with sickle cell disease. Transfusions and/or exchange transfusions first demonstrated their effectiveness in reducing recurrent strokes in SCD. Transfusions have also proved to be effective prophylaxis in high risk patients for the first stroke and in other complications such as acute chest syndrome.12,13

The severity and mechanism of body iron overload in SCD is completely different compared to the iron overload that occurs in thalassemia major. Transfusion-acquired iron overload in the heart is rare in sickle cell disease, probably because iron released by transfusion and haemolysis is efficiently handled by the effective erythropoiesis of sickle cell disease, but not as well by the ineffective erythropoiesis in thalassaemia.2,14,15

Sickle cell disease is also associated with a chronic inflammatory state and increased haemolytic status related to vasculocclusive crisis.

Consequentially, guidelines such as those in the UK currently recommend initiating iron chelation therapy in patients with SCD once LIC increases to >7 mg Fe/g dry weight if serum ferritin steady-state levels are >1000 μg/l, or at least 20 top-up transfusions.16

The gold standard for assessing liver iron stores is the hepatic iron content determined by liver biopsy, but this technique is limited because it is invasive and carries a risk of complications. Noninvasive methods including blood tests and imaging techniques have been evaluated and considered in greater detail.17,18,19

Studies of liver biopsies in patients with SCD have linked transfusional iron load with LIC, fibrosis, and cirrhosis. If transfusion is given without chelation, portal fibrosis can develop as early as two years after transfusion. With sequential biopsies, increased fibrosis was found in 1/3 of patients with LIC values > 9 mg/g dry weight and in direct proportion to the LIC.20,16

TE is an ultrasound-based tool for measuring liver stiffness as a surrogate of fibrosis that is widely used due to its high accuracy for the diagnosis of fibrosis stage.21,22

Liver stiffness also correlates with cirrhosis complications including variceal hemorrhage, ascites, and hepatocellular carcinoma (HCC). The iron effect in the pathogenesis of fibrosis due to increased oxidative stress and other pathological modes of action of HCV, ethanol, and steatosis, lead to mitochondrial dysfunction and hepatocyte apoptosis.23 Hepatocellular carcinoma following liver cirrhosis as a complication of chronic hepatitis C and iron overload has been reported in thalassemia patients.24,25 Cirrhosis, is the strongest and the most common known risk factor for HCC, is frequently found in thalassaemia patients as it has been described from the Italian Registry.24,25,26,27

In Drasar’s research paper (2016) have shown that transfusion and markers of iron overload were weakly but significantly correlated with T.E and enhanced liver fibrosis score (ELF) using standard markers of liver function.21

In our study LIC, LSM and serum ferritin level were significantly reduced after 12 months of deferasirox treatment indicating that over 12 months, deferasirox significantly reduced liver iron burden in these iron-overloaded patients with SCD.

Also, ALT, AST, and LDH levels significantly decreased after 12 months of therapy suggestive an improvement of liver inflammation. Furthermore, ferritin and LIC significantly correlate with hepatic stiffness before and after deferasirox administration suggesting that reduction of iron in the liver leads to stiffness improvement. Our results are in agreement with Deugnier (2011) and Adams (2011) that deferasirox can lead to regression of fibrosis, improving liver stiffness and correlating with iron removed.28,29

Adequate chelation therapy is mandatory to prevent liver disease progression in sickle cell disease patients.

Additionally both AST and ALT showed significant improvement over the course of the study but showed no correlation with liver stiffness. Although transaminases are markers of inflammatory liver reaction and is well established that high levels influence the elastographic findings, the absence of correlation in our study is due to mildly increased levels of transaminases at the onset of the study.

Hs-CRP remained stable from the beginning to the end of the study, and show no correlation with ferritin or other parameters.
In addition, studies of deferasirox in patients with thalassemia provided evidence of significant reduction in hepatic fibrosis irrespective of hepatic iron concentration or HCV prevalence. Our results clearly demonstrate that the observed improved of hepatic stiffness is mainly associated with the reduction of hepatic iron and not by the improvement of inflammatory status. 30,31

Patients with the sickle cell disease are at risk for significant hepatic complications, and better definitions and markers could be utilized to understand the pathophysiology of hepatic involvement. Taken together, these results suggest that TE is a useful and less expensive than the MRI tool to identify the stage of stiffness/fibrosis in patients with SCD at steady state and to monitor the efficacy of chelation therapy.

Conclusions. In this study, LSM shows a strong relationship with LIC. Both baseline LSM and LIC changed and correlated with ferritin at the end of the study. The efficacy of deferasirox in hepatic iron removal in patients with sickle cell disease also improves the inflammatory response. Transient Elastography (TE) is a useful tool for assessing the response of liver iron chelation, it is much more widely accessible, and it is also useful for more intensive surveillance of liver stiffness. TE is a relatively low cost easy to perform the test, with high accuracy evaluating liver stiffness in this patients reflecting both fibrosis and hemosiderosis on the top of surrogates markers of iron overload.

References:


